Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jean-Claude Tardif CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS

Jean-Claude Tardif CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS

Director, MHI Research Center, Professor of Medicine, Canada Research Chair in translational and personalized medicine, University of Montreal endowed research chair in atherosclerosis, Montreal Heart Institute, Montreal, Quebec

Disclosures

Disclosures: Dr. Tardif has received research grants from Amarin, AstraZeneca, DalCor, Esperion, Ionis, RegenXBio, Sanofi and Servier; honoraria from DalCor, HLS, Sanofi and Servier; holds minor equity interest in DalCor; and is an author of patents on pharmacogenomics-guided CETP inhibition and the use of colchicine after myocardial infarction.

Recent Contributions to PracticeUpdate:

  1. Colchicine in Patients With Acute Coronary Syndrome

Most Read This Week

Recently Updated